CAS 2134602-45-0

Formula: C19H18Cl3N3O

InChI: InChI=1S/C19H18Cl3N3O/c20-13-3-1-12(2-4-13)11-24-7-5-14(6-8-24)25-18-10-16(22)15(21)9-17(18)23-19(25)26/h1-4,9-10,14H,5-8,11H2,(H,23,26)

InChI key: LAGUDYUGRSQDKS-UHFFFAOYSA-N

SMILES: C1CN(CCC1N2C3=CC(=C(C=C3NC2=O)Cl)Cl)CC4=CC=C(C=C4)Cl

5,6-Dichloro-1-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one

CAS: 2134602-45-0

Formula: C₁₉H₁₈Cl₃N₃O

Purity: 98%

Color and Shape: Solid

Molecular weight: 410.7247

Ref: IN-DA01EOCE

SR17018

CAS: 2134602-45-0

SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM.

Formula: C₁₉H₁₈Cl₃N₃O

Purity: 99.89%

Color and Shape: Solid

Molecular weight: 410.72

Ref: TM-T4407

SR17018

Controlled Product

CAS: 2134602-45-0

SR17018 is a drug that is used for the treatment of depression and pain. It acts as a phosphatase inhibitor, and has been shown to have potent inhibitory activity against protein phosphatases 1 and 2A. SR17018 has been demonstrated to be safe and well tolerated in clinical studies. In addition, this drug has shown significant effects on depression, with less adverse effects than traditional antidepressant drugs. These effects may be due to its ability to dephosphorylate proteins that are involved in neuronal signaling pathways in the brain. This drug also has an antinociceptive effect on pain models in mice by inhibiting the primary hippocampal neurons from sending signals to nerve cells that control pain perception. SR17018 can be used as an alternative or adjunct therapy for depression and chronic pain conditions.

Formula: C₁₉H₁₈Cl₃N₃O

Purity: Min. 95%

Molecular weight: 410.72 g/mol

Ref: 3D-JKD60245